Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study ...

relative to quarterly Skyrizi maintenance dosing,” the analysts added in a March 10 note. The clinical wins didn't end with psoriasis either. Monday morning, J&J also announced that icotrokinra ...

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...